Skip to main content

Clinical Trials Using Tocilizumab

Review the clinical trials studying tocilizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

Tocilizumab for the Treatment of Progressive or Recurrent Pediatric Adamantinomatous Craniopharyngioma
Status: Active
Location: 6 locations
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 10 locations
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Status: Active
Location: 10 locations
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Status: Active
Location: 8 locations
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 7 locations
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 6 locations
Chemotherapy with or without Tocilizumab for the Initial Treatment of Unresectable, Locally Recurrent, or Metastatic Triple Negative or ER and PR-low Breast Cancer
Status: Active
Location: 4 locations
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Active
Location: 5 locations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Active
Location: 4 locations
Atezolizumab with or without Tocilizumab or Etrumadenant in Treating Men with Localized Prostate Cancer before Radical Prostatectomy
Status: Active
Location: 3 locations
Atezolizumab with or without Tocilizumab, Tiragolumab, or Other Immune Modulating-Agents in Treating Patients with Head and Neck Squamous Cell Cancer
Status: Active
Location: 2 locations
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Status: Active
Location: 3 locations
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Status: Active
Location: 3 locations
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Status: Active
Location: 3 locations
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Status: Active
Location: 3 locations
In Situ Immunomodulation for Unresectable and Metastatic Solid Tumors
Status: Active
Location: 2 locations
Elranatamab, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Tocilizumab and Atezolizumab for the Treatment of Patients with Refractory, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Venetoclax and Tocilizumab for the Treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Status: Active
Location: See ClinicalTrials.gov